A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies

Brief description of study

The purpose of the study is to determine the safety and efficacy of Adavosertib (AZD1775) for patients who have locally advanced, or metastatic solid tumor malignancy or metastatic clear cell renal cell carcinoma. The study drug AZD1775 is an investigational drug, which means it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States.


Clinical Study Identifier: s19-01539
ClinicalTrials.gov Identifier: NCT03284385
Principal Investigator: Victor Ricardo Adorno Febles.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.